Scholarlink

Background <p>Psoriasis is a chronic, immune-mediated disease with an overabundance of cytokines and aberrant keratinocyte proliferation.</p> Objective <p>To assess the therapeutic activity of topical application of 10% sulfasalazine in an imiquimod-induced murine model and to compare its therapeutic activity with that of clobetasol.</p> Methodology <p>Thirty-two male mice were randomly assigned into four groups, with each group consisting of eight individuals: normal control group, IMQ + vehicle group, IMQ + clobetasol group, and IMQ + 10% sulfasalazine group. IMQ was administered for 7 days, and then daily topical application was conducted for 14 days. Lesion severity was determined by PASI scores, and histological scores and concentrations of TNF-α and IL-6.</p> Results <p>Both sulfasalazine and clobetasol led to significant reduction in PASI scores, compared to IMQ + vehicle (<i>p</i> &lt; 0.05). The regimen of sulfasalazine improved epidermal structure, acanthosis, and inflammation, as well as.</p> Conclusion <p>Topical sulfasalazine was found to possess significant anti-inflammatory activity, both clinical and histological, against IMQ-induced inflammation resembling psoriasis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Topical 10% sulfasalazine ointment attenuates imiquimod-induced psoriasiform inflammation in mice compared with clobetasol

  • 期刊论文

  • 发表日期：

    2026年1月16日

查看全文
  • Mohammed Abdul Muttalib Abdul Bari

摘要

Background

Psoriasis is a chronic, immune-mediated disease with an overabundance of cytokines and aberrant keratinocyte proliferation.

Objective

To assess the therapeutic activity of topical application of 10% sulfasalazine in an imiquimod-induced murine model and to compare its therapeutic activity with that of clobetasol.

Methodology

Thirty-two male mice were randomly assigned into four groups, with each group consisting of eight individuals: normal control group, IMQ + vehicle group, IMQ + clobetasol group, and IMQ + 10% sulfasalazine group. IMQ was administered for 7 days, and then daily topical application was conducted for 14 days. Lesion severity was determined by PASI scores, and histological scores and concentrations of TNF-α and IL-6.

Results

Both sulfasalazine and clobetasol led to significant reduction in PASI scores, compared to IMQ + vehicle (p < 0.05). The regimen of sulfasalazine improved epidermal structure, acanthosis, and inflammation, as well as.

Conclusion

Topical sulfasalazine was found to possess significant anti-inflammatory activity, both clinical and histological, against IMQ-induced inflammation resembling psoriasis.